Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Download Data

Freeline Therapeutics Holdings Plc Price to Book Ratio (P/B) on February 29, 2024

Freeline Therapeutics Holdings Plc Price to Book Ratio (P/B) is NA on February 29, 2024, a NA change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.
  • Freeline Therapeutics Holdings Plc 52-week high Price to Book Ratio (P/B) is 8,734.03 on March 06, 2023, which is NA below the current Price to Book Ratio (P/B).
  • Freeline Therapeutics Holdings Plc 52-week low Price to Book Ratio (P/B) is 0.18 on June 09, 2023, which is NA below the current Price to Book Ratio (P/B).
  • Freeline Therapeutics Holdings Plc average Price to Book Ratio (P/B) for the last 52 weeks is 1,562.74.
NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO Mr. Michael J. Parini J.D.
IPO Date Aug. 7, 2020
Location United Kingdom
Headquarters Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees 152
Sector Healthcare
Industry Biotechnology
Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Similar companies

AVRO

AVROBIO Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email